RJA
DGX icon

Raymond James & Associates’s Quest Diagnostics DGX Stock Holding History

Raymond James & Associates’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-12,500
Closed -$221K – 2289
2015
Q2 		$221K Sell
12,500
-300
-2% -$22.1K ﹤0.01% 2355
2015
Q1 		$296K Buy
+12,800
New +$917K ﹤0.01% 2220

Other funds holding DGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DSA
Davis Selected Advisers Tucson, Arizona $21.8B AUM 23.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Grantham, Mayo, Van Otterloo & Co (GMO)
Grantham, Mayo, Van Otterloo & Co (GMO) Boston, Massachusetts $39.1B AUM 28.69% 1-Year Est. Return

Raymond James & Associates's DGX Position: Q3 2024 in Review

Raymond James & Associates increased its Quest Diagnostics (DGX) stake by 12% in Q3 2024, buying an estimated $2.23M and bringing the position to 140,982 shares worth $21.9M. The position accounts for 0.01% of the portfolio, ranked #767.

Raymond James & Associates first reported a position in DGX in Q3 2013 and has held it in 45 quarters since. The position peaked at $43.5M in Q2 2016. 847 funds tracked by Wall St. Rank hold DGX as of Q3 2024.

  • Raymond James & Associates held 140,982 shares of Quest Diagnostics worth $21.9M as of Q3 2024.
  • Raymond James & Associates bought 14,899 Quest Diagnostics shares in Q3 2024, an estimated $2.23M.
  • Quest Diagnostics made up 0.01% of Raymond James & Associates's portfolio in Q3 2024, its #767 holding.
  • Raymond James & Associates first reported a position in Quest Diagnostics in Q3 2013 and has held it in 45 quarters since.
  • Raymond James & Associates's Quest Diagnostics position peaked at $43.5M in Q2 2016.
  • 847 funds tracked by Wall St. Rank held Quest Diagnostics as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.